Canopy’s stock reversed on earnings after seeing a rally sparked by the possibility of marijuana reform in the U.S.

Alliance Global Partners analyst Aaron Grey lowered the firm’s price target on Canopy Growth (CGC) to C$4 from C$7 and keeps a Neutral rating ...

Canopy Growth Q3 sales hit C$74.76 million, surpassing estimates. Medical cannabis revenue rose 16%, while adjusted EBITDA loss improved 61% year-over-year.

Reports Q3 revenue C$74.8M vs. C$78.5M last year. “Canopy Growth’s (CGC) third quarter highlights that our business has the right ingredients ...

Canopy Growth Corporation (CGC) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $1.79 per share a year ago. These ...

Canopy Growth Corporation’s CGC share price has surged by 22.22%, which has investors questioning if this is right time to sell.

The most recent trading session ended with Canopy Growth Corporation (CGC) standing at $1.97, reflecting a -1.01% shift from the previouse trading day's closing. This move lagged the S&P 500's daily ...

Not only does Canopy Growth still have a lot of debt remaining, its cash flow from operations continues to be negative. Often, tangible book value can help support a stock price, but this doesn't ...

“The uncertainty in the sector and weak investor sentiment has kept cannabis stock prices on the downtrend,” noted Seeking Alpha analyst Alan Sumler. “Canopy Growth is underperforming ...